A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/706 (2006.01) A61K 31/7064 (2006.01) A61K 31/7068 (2006.01) A61K 31/7072 (2006.01) A61K 31/7076 (2006.01) A61K 31/708 (2006.01) A61P 27/02 (2006.01) C07H 19/10 (2006.01) C07H 19/20 (2006.01) C07H 19/207 (2006.01)
Patent
CA 2408842
The present invention provides a method of preventing or treating retinal degeneration arising from pathophysiological or physical conditions. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor ligand, in an amount effective to elevate its extracellular concentration to activate retinal glial and neuronal cell surface P2Y receptors and mount a neuroprotective response. Methods of administering including intravitreal bolus and sustained administrations, transscleral delivery, topical, and systemic administrations. The pharmaceutical composition useful in this invention comprises a P2Y purinergic receptor agonist, which include uridine 5'-di -and triphosphate (UDP, UTP) and their analogs, adenosine 5'-diphosphate (ADP) and its analogs, cytidine 5'-di- and triphosphate (CDP, CTP) and their analogs, and dinucleoside polyphosphate compounds.
L'invention concerne un procédé de prévention ou de traitement de la dégénérescence rétinienne résultant de conditions pathophysiologiques ou physiques, qui consiste à administrer au patient une composition pharmaceutique renfermant un ligand de récepteur purinergique P2Y, en quantité efficace pour élever sa concentration extracelullaire de manière à activer les récepteurs P2Y de surface cellulaire gliale et neuronale et à induire une réponse neuroprotectrice. L'invention concerne également des procédés d'administration, y compris le bolus intravitréen et l'administration prolongée, l'administration transsclérale, topique, et systémique. La composition pharmaceutique décrite comprend un agoniste de récepteur purinergique P2Y, avec uridine 5'- di-et triphosphate (UDP, UTP) y compris leurs analogues, adénosine 5'-diphosphate (ADP) y compris leurs analogues, cytidine 5'- di-et triphosphate (CDP, CTP) y compris leurs analogues, et composés de polyphosphate dinucléoside.
Gowling Lafleur Henderson Llp
Inspire Pharmaceuticals Inc.
LandOfFree
Method for treating retinal degeneration with purinergic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating retinal degeneration with purinergic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating retinal degeneration with purinergic... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1978444